About Cagrilintide
Cagrilintide is studied as a long-acting amylin analogue in metabolic research. Supplied as a lyophilized powder for laboratory investigations of amylin receptor pharmacology, satiety-associated signaling markers, and glucose-regulatory mechanisms in controlled experimental models. Each batch undergoes analytical verification for identity and purity using HPLC and mass spectrometry. Supplied as: Lyophilized powder Purity: 99%+ (HPLC verified) Storage: Store desiccated at ?20�C for long-term. Short-term room temperature exposure (around 1 month) during shipping/handling is generally acceptable if kept sealed, dry, and protected from heat/light. Designation: FOR RESEARCH USE ONLY. Not intended for human or animal consumption.
Latest Research
Co-agonism of GLP-1R and CTR/AMYR in the lateral dorsal tegmental nucleus produces additive effects on homeostatic and motivated feeding.
Recent research on Cagrilintide: Co-agonism of GLP-1R and CTR/AMYR in the lateral dorsal tegmental nucleus produces additive effects on homeostatic and motivated feeding.
Read Full Study on PubMedNew Amylin-Based Agonists for the Treatment of Obesity and Type 2 Diabetes Mellitus.
Recent research on Cagrilintide: New Amylin-Based Agonists for the Treatment of Obesity and Type 2 Diabetes Mellitus.
Read Full Study on PubMedAdditional Studies
Continued CagriSema treatment preserves weight loss by reducing energy intake and maintaining energy expenditure in rats.
Recent research on Cagrilintide: Continued CagriSema treatment preserves weight loss by reducing energy intake and maintaining energy expenditure in rats.
Read on PubMedEfficacy and Safety of CagriSema in Type 2 Diabetes: A Dose- and Comparator-Specific Systematic Review and Bayesian Meta-Analysis.
Recent research on Cagrilintide: Efficacy and Safety of CagriSema in Type 2 Diabetes: A Dose- and Comparator-Specific Systematic Review and Bayesian Meta-Analysis.
Read on PubMedDesign and baseline characteristics of the CagriSema cardiovascular outcomes trial (REDEFINE 3).
Recent research on Cagrilintide: Design and baseline characteristics of the CagriSema cardiovascular outcomes trial (REDEFINE 3).
Read on PubMedGastrointestinal adverse effects of GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists: A narrative expert review of approved therapies, oral formulations, and pipeline agents.
Recent research on Cagrilintide: Gastrointestinal adverse effects of GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists: A narrative expert review of approved therapies, oral formulations, and pipeline agents.
Read on PubMedEfficacy of CagriSema for Reaching Anthropometric Treatment Targets and Cardiometabolic Outcomes: A Secondary, Post hoc Analysis of REDEFINE 1.
Recent research on Cagrilintide: Efficacy of CagriSema for Reaching Anthropometric Treatment Targets and Cardiometabolic Outcomes: A Secondary, Post hoc Analysis of REDEFINE 1.
Read on PubMedCagrilintide and retatrutide combination therapy enhances weight loss and metabolic outcomes in obese male rats.
Recent research on Cagrilintide: Cagrilintide and retatrutide combination therapy enhances weight loss and metabolic outcomes in obese male rats.
Read on PubMedRelated Research
Purchase Cagrilintide from Verified Peptides
High-purity research peptides with full analytical verification
- 99% Purity (HPLC Verified)
- Full Certificate of Analysis
- Same Day Dispatch
- Free UK Shipping Over £75
Research Disclaimer
The research articles and studies referenced on this page are for informational purposes only. All products are sold for research use only and are not intended for human or animal consumption. The information provided does not constitute medical advice, diagnosis, or treatment. Always consult with qualified healthcare professionals before making any decisions related to health or medical treatment.
